Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Diffuse Large B-Cell Lymphoma (DLBCL)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Contact: Study coordinator (Hui Liu) · sylen@zju.edu.cn · +86 13819198629

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation

Diffuse Large B-Cell Lymphoma (DLBCL)

Abroad (travel likely)RecruitingPHASE2

Suzhou, China

Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET

Diffuse Large B-Cell Lymphoma · DLBCL

Abroad (travel likely)Recruiting

Shanghai, China

Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission

Diffuse Large B-Cell Lymphoma

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Tianjin, China